Our research team is focused on identifying patients with transthyretin cardiac amyloidosis (ATTR-CA) as soon as possible before signs and/or symptoms develop. Early diagnosis is key to best leveraging therapies for ATTR-CA as they work better early in the course of the illness. We are using previously obtained lumbar spine stenosis specimens for identification of individuals who may have ATTR-CA. With funding from the NIA, our study could change clinical practice by allowing for early identification of those who develop this disorder. Without recognition and treatment, transthyretin cardiac amyloidosis is a progressive, highly morbid, and fatal disease. However, with early identification, it is easily managed.